Neisseria meningitidis serogroup C capsular polysaccharide conjugate

The Neisseria meningitidis serogroup C capsular polysaccharide conjugate is not a receptor, enzyme, or classical drug target but instead refers to the active antigenic component of a conjugate vaccine. The serogroup C *N. meningitidis* capsule is composed of an (α2→9)-linked polysialic acid polymer, a critical virulence factor for bacterial invasiveness. For vaccine purposes, this polysaccharide is chemically conjugated to a carrier protein (frequently CRM197, a non-toxic mutant of diphtheria toxin, or tetanus toxoid) to convert the immune response from T-cell–independent to T-cell–dependent, leading to immune memory, high antibody titers, and long-lasting protection. Conjugate vaccines based on this antigen have been highly effective in reducing incidence of serogroup C meningococcal disease, especially in young children, who respond poorly to plain polysaccharide vaccines. This entry is not a molecular target in the pharmacological sense, but a vaccine antigen, so common drug-target framework categories do not directly apply. The correct canonical target would be the serogroup C capsular polysaccharide (the antigen), or, in a vaccine context, the polysaccharide conjugate as a vaccine component, but neither is a receptor, enzyme, or molecular target for small-molecule therapeutics. The query describes a vaccine antigen (a conjugated polysaccharide), not a molecular target like a receptor, enzyme, or transporter as typically defined in pharmacology. Thus, it does not fit standard therapeutic target frameworks and is not a molecular target for drugs, but rather is used as an immunogen in vaccines.

Other names

Neisseria meningitidis group C capsular polysaccharide–protein conjugateGroup C meningococcal polysaccharide conjugateMenC conjugate

Induces protective immune response (as a conjugate vaccine component, facilitates T-cell dependent antibody generation when linked to a carrier protein)